Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis.

      Highlights

      • Robotic neurorehabilitation plus OAT may be effective in improving MS spasticity.
      • We tested the efficacy of Nabiximols with OAT and neurorobotics.
      • The coupled therapy may shape common neuroplasticity mechanisms for spasticity.
      • The coupled therapy is preliminarily demonstrated as safe and efficacious.

      Abstract

      Background

      Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system, affecting ambulation even in people with only mild neurological signs. Patients with MS frequently experience spasticity, which contributes significantly to impair their motor functions, including ambulation, owing to muscle stiffness, spasms, and pain.

      Objectives

      To clarify the role of delta-9-tetrahydrocannabinol(THC):cannabidiol(CBD) oromucosal spray, coupled to robot-aided gait training (RAGT) using the Lokomat©Pro to improve functional ambulation in patients with MS.

      Methods

      We compared 20 patients with MS, who were treated with THC:CBD oromucosal spray in add-on to the ongoing oral antispastic therapy (OAT) (group A), with 20 individuals with MS (matched for clinical-demographic characteristics) who were treated only with OAT (group B). Both the groups underwent RAGT using the Lokomat-Pro (three 45-minute sessions per week). Our primary outcome measures were the Functional Independence Measure (FIM) and the 10 meters walking test (10MWT). As secondary outcome measures we evaluated the brain cortical excitability by using Transcranial Magnetic Stimulation. Both parameters were taken before and after the end of the RAGT.

      Results

      FIM improved in group A more than in group B (p<0.001). Moreover, 10MWT decreased in group A more than in group B (p<0.001). These clinical findings were paralleled by a more evident reshape of intracortical excitability in both upper and lower limbs, as suggested by motor evoked potential amplitude increase (p<0.001), intracortical inhibition strengthening (p<0.001), and intracortical facilitation decrease (p=0.01) in group A as compared to group B.

      Conclusions

      Our results suggest that the combined THC:CBD-RAGT approach could be useful in improving gait performance in patients with MS.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Ansari NN
        • Naghdi S
        • Moammeri H
        • Jalaie S
        Ashworth scales are unreliable for the assessment of muscle spasticity.
        Physiother. Theory Pract. 2006; 22: 119-125
        • Anwar K.
        • Barnes M.P.
        A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis.
        NeuroRehabilitation. 2009; 24: 333-340
        • Bachtiar V.
        • Stagg C.J.
        The role of inhibition in human motor cortical plasticity.
        Neuroscience. 2014; 278C: 93-104
        • Benedetti M.G.
        • Piperno R.
        • Simoncini L.
        • Bonato P.
        • Tonini A.
        • Giannini S.
        Gait abnormalities in minimally impaired multiple sclerosis patients.
        Mult Scler. 1999; 5: 363-368
        • Bethoux F
        • Marrie R.A.
        A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis.
        Patient - Patient-Centered Outcomes Res. December 2016; 9: 537-546
        • Brosseau L.
        • Wolfson C.
        The inter-rater reliability and construct validity of the functional independence measure for multiple sclerosis subjects.
        Clin. Rehabil. 1994; 8: 107-115
        • Calabrò R.S.
        • Accorinti M.
        • Porcari B.
        • Carioti L.
        • Ciatto L.
        • Billeri L.
        • Andronaco V.
        • Galletti F.
        • Serena F.
        • Naro A.
        Does hand robotic rehabilitation improve motor function by rebalancing interhemispheric connectivity after chronic stroke? Encouraging data from a randomised-clinical-trial.
        Clin. Neurophysiol. 2019; : 130
        • Calabrò R.S.
        • D'Aleo G.
        • Sessa E.
        • Leo A.
        • De Cola M.C.
        • Bramanti P.
        Sexual dysfunction induced by intrathecal baclofen administration: is this the price to pay for severe spasticity management?.
        J. Sex Med. 2014; 11: 1807-1815
        • Calabrò R.S.
        • Naro A.
        • Russo M.
        • Milardi D.
        • Leo A.
        • Filoni S.
        • Trinchera A.
        • Bramanti P.
        Is two better than one? Muscle vibration plus robotic rehabilitation to improve upper limb spasticity and function: A pilot randomized controlled trial.
        PLoS One. 2017; 12e0185936
        • Calabrò R.S.
        • Russo M.
        • Naro A
        Who may benefit from armeo power treatment? A neurophysiological approach to predict neurorehabilitation outcomes.
        PM R. 2016; 8: 971-978
        • Calabrò R.S.
        • Russo M.
        • Naro A.
        • et al.
        Robotic gait training in multiple sclerosis rehabilitation: can virtual reality make the difference? Findings from a randomized controlled trial.
        J. Neurol. Sci. 2017; 377: 2530
        • Chen R.
        • Tam A.
        • Bütefisch C.
        • Corwell B.
        • Ziemann U.
        • Rothwell J.C.
        • Cohen L.G.
        Intracortical inhibition and facilitation in different representations of the human motor cortex.
        J. Neurophysiol. 1998; 80: 2870-2881
        • Clarkson A.N.
        • Huang B.S.
        • Macisaac S.E.
        • Mody I.
        • Carmichael S.T.
        Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke.
        Nature. 2010; 468: 305-309
        • Coghe G.
        • Pau M.
        • Corona F.
        • et al.
        Walking improvements with nabiximols in patients with multiple sclerosis.
        J. Neurol. 2015; 262: 2472-2477
        • Confavreux C.
        • Vukusic S.
        • Moreau T.
        • et al.
        Relapses and progression of disability in multiple sclerosis.
        N. Engl. J. Med. 2000; 343: 1430-1438
        • Duffell L.D.
        • Brown G.L.
        • Mirbagheri M.M.
        Facilitatory effects of anti-spastic medication on robotic locomotor training in people with chronic incomplete spinal cord injury.
        J. Neuroeng. Rehabil. 2015; 20: 12-29
        • Erbil D.
        • Tugba G.
        • Murat T.H.
        • et al.
        . Effects of robot-assisted gait training in chronic stroke patients treated by botulinum toxin-a: a pivotal study.
        Physiother. Res. Int. 2018; 3: 718
        • Farrar JT
        • Troxel AB
        • Stott C
        • Duncombe P
        • Jensen MP
        Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.
        Clin. Ther. 2008 May; 30: 974-985
        • Filli L.
        • Sutter T.
        • Easthope C.S.
        • Killeen
        • et al.
        Profiling walking dysfunction in multiple sclerosis: characterization, classification and progression over time.
        Sci. Rep. 2018; 8: 4984
        • Friedman D.
        • French J.A.
        • Maccarrone M.
        Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders.
        Lancet Neurol. 2019; : 18
        • Gassert R.
        • Dietz V.
        Rehabilitation robots for the treatment of sensorimotor deficits: a neurophysiological perspective.
        J. Neuroeng. Rehabil. 2018; 15: 46
        • Ghotbi N.
        • Ansari N.N.
        • Naghdi S.
        • Hasson S.
        Measurement of lower-limb muscle spasticity: Intrarater reliability of Modified Modified Ashworth Scale.
        J. Rehabil. Res. Dev. 2011; 48: 83 — 88
        • Giacoppo S.
        • Bramanti P.
        • Mazzon E.
        Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation.
        Mult. Scler. Relat. Disord. 2017; 2017: 22-31
        • Giacoppo S.
        • Mandolino G.
        • Galuppo M.
        • Bramanti P.
        • Mazzon E.
        Cannabinoids: new promising agents in the treatment of neurological diseases.
        Molecules. 2014; 19: 18781-18816
        • Gold R.
        • Oreja-Guevara C.
        Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.
        Expert. Rev. Neurother. 2013; 13: 55-59
        • Heesen C.
        • Bohm J.
        • Reich C.
        • et al.
        Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable.
        Mult. Scler. 2008; 14: 988-991
        • Hudson R
        • Renard J
        • Norris C
        • Rushlow WJ
        Laviolette SR cannabidiol counteracts the psychotropic side-effects of Δ-9-tetrahydrocannabinol in the ventral hippocampus through bi-directional control of ERK1-2 phosphorylation.
        J. Neurosci. 2019 Sep 30; (pii: 0708-19)
        • Ivanenko Y.P.
        • Poppele R.E.
        • Lacquaniti F.
        Distributed neural networks for controlling human locomotion: lessons from normal and SCI subjects.
        Brain Res. Bull. 2009; 78: 13-21
        • Katz S.I.
        Classification, diagnosis, and differential diagnosis of multiple sclerosis.
        Curr. Opin. Neurol. 2015; 28: 193-205
        • Kieseier B.C.
        • Pozzilli C.
        Assessing walking disability in multiple sclerosis.
        Mult. scler. (Houndmills, Basingstoke, Engl.). 2012; 18: 914-924
        • Kister I
        • Bacon TE
        • Chamot E
        • Salter AR
        • Cutter GR
        • Kalina JT
        • Herbert J
        Natural history of multiple sclerosis symptoms.
        Int. J. M.S. Care. 2013; 15 (Fall): 146-158
        • Koch G
        • Mori F
        • Codecà C
        • Kusayanagi H
        • Monteleone F
        • Buttari F
        • Fiore S
        • Bernardi G
        • Centonze D
        Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans.
        Brain Stimul. 2009; 2: 22933
        • Kujirai T.
        • Caramia M.D.
        • Rothwell J.C.
        • et al.
        Corticocortical inhibition in human motor cortex.
        J. Physiol. 1993; 471: 501-519
        • Larocca N.G.
        Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners.
        Patient. 2011; 4: 189-201
        • Leocani L
        • Chieffo R
        • Gentile A
        • Centonze D
        Beyond rehabilitation in MS: insights from non-invasive brain stimulation.
        Mult. Scler. 2019; 25: 1363-1371
        • Leocani L.
        • Nuara A.
        • Houdayer E.
        • et al.
        Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.
        J. Neurol. 2015; 262: 2520-2527
        • Leussink V.I.
        • Husseini L.
        • Warnke C.
        • Broussalis E.
        • Hartung H.P.
        • Kieseier B.C.
        Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.
        Ther. Adv. Neurol. Disord. 2012; 5: 255-266
        • Liepert J.
        • Hamzei F.
        • Weiller C.
        Motor cortex disinhibition of the unaffected hemisphere after acute stroke.
        Muscle Nerve. 2000; 23: 1761-1763
        • Lizrova Preiningerova J.
        • Novotna K.
        • Rusz J.
        • Sucha L.
        • Ruzicka E.
        • Havrdova E.
        Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).
        J. Neuroeng. Rehabil. 2015; 10: 12-14
        • McDonnell Michelle
        • Stinear Cathy
        TMS measures of motor cortex function after stroke: a meta-analysis.
        Brain Stimulation. 2017;
        • Merrick J.
        • Lane B.
        • Sebree T.
        • Yaksh T.
        • O'Neill C.
        • Banks S.L.
        Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid.
        Cannabis Cannabinoid Res. 2016; 1: 102-112
        • Mirbagheri M.M.
        Comparison between the therapeutic effects of robotic-assisted locomotor training and an anti-spastic medication on spasticity.
        Conf. Proc. IEEE Eng. Med. Biol. Soc. 2015; : 4675-4678
        • Mori F.
        • Kusayanagi H.
        • Monteleone F.
        • Moscatelli A.
        • Nicoletti C.G.
        • Bernardi G.
        • Centonze D.
        Short interval intracortical facilitation correlates with the degree of disability in multiple sclerosis.
        Brain Stimul. 2013; 6: 67-71
        • Nakamura H.
        • Kitagawa H.
        • Kawaguchi Y.
        • Tsuji H.
        Direct and indirect activation of human corticospinal neurons by transcranial magnetic and electrical stimulation.
        Neurosci Lett. 1996; 24: 45-48
        • Nantes J.C.
        • Zhong J.
        • Holmes S.A.
        • Narayanan S.
        • Lapierre Y.
        • Koski L.
        Cortical damage and disability in multiple sclerosis: relation to intracortical inhibition and facilitation.
        Brain Stimul. 2016; 9: 566-573
        • Nielsen S.
        • Murnion B.
        • Campbell G.
        • Young H.
        • Hall W.
        Cannabinoids for the treatment of spasticity.
        Dev. Med. Child Neurol. 2019; 61: 631-638
        • Panitch H.
        • Applebee A
        Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.
        Expert Opin. Pharmacother. 2011; 12: 1511-1521
        • Russo M.
        • Calabrò R.S.
        • Naro A.
        • et al.
        . Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation.
        Neural Plast. 2015;
        • Russo M.
        • Dattola V.
        • Logiudice A.L.
        • et al.
        The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: rationale, study design, and methodology.
        Medicine (Baltimore). 2017; 96: e8826
        • Russo M.
        • De Luca R.
        • Torrisi M.et.al
        Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study.
        Eur. Rev. Med. Pharmacol. Sci. 2016; 20: 3127-3133
        • Schwid S.R.
        • Goodman A.D.
        • Mattson D.H.
        • Mihai C.
        • Donohoe K.M.
        • Petrie M.D.
        • Scheid E.A.
        • Dudman J.T.
        • McDermott M.P.
        The measurement of ambulatory impairment in multiple sclerosis.
        Neurology. 1997; 49: 1419-1424
        • Seo H.Y.
        • Kim G.W.
        • Won Y.H.
        • Park S.H.
        • Seo J.H.
        • Ko M.H.
        Changes in intracortical excitability of affected and unaffected hemispheres after stroke evaluated by paired-pulse transcranial magnetic stimulation.
        Ann. Rehabil. Med. 2018; 42: 495-501
        • Shakespeare D.T.
        • Boggild M.
        • Young C.
        Anti-spasticity agents for multiple sclerosis.
        Cochrane Database Syst. Rev. 2003; 4CD001332
        • Squintani G.
        • Donato F.
        • Turri M.
        • et al.
        . Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
        J. Neurol. Sci. 2016; 370: 263-268
        • Straudi S.
        • Benedetti M.G.
        • Venturini E.
        • Manca M.C.
        • Foti N.
        Does robotassisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized- control trial.
        NeuroRehab. 2013; 33: 555-563
        • Straudi S.
        • Manfredini F.
        • Lamberti N.
        • et al.
        The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressive Multiple sclerosis patients (RAGTIME): study protocol for a randomized controlled trial.
        Trials. 2017; 18: 88
        • Syed Y.Y.
        • McKeage K.
        • Scott L.J.
        Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
        Drugs. 2014; 74: 563-578
        • Valet M.
        • Quoilin M.
        • Lejeune T.
        • Stoquart G.
        • Van Pesch V.
        • El Sankari S.
        • Detrembleur C.
        • Warlop T.
        Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis.
        CNS drugs. 2019; 33: 1087-1099
        • van Munster CEP
        • et al.
        Outcome measures in clinical trials for multiple sclerosis.
        CNS Drugs. 2017; 31: 217-236
        • Wade D.T.
        • Collin C.
        • Stott C.
        • Duncombe P.
        Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis.
        Mult. Scler. 2010; 16: 707-714
        • Werhahn K.J.
        • Classen J.
        • Benecke R.
        The silent period induced by transcranial magnetic stimulation in muscles supplied by cranial nerves: normal data and changes in patients.
        J. Neurol. Neurosurg. Psychiatry. 1995; 59: 586-596
        • Yalachkov Y.
        • Soydaş D.
        • Bergmann J.
        • Frisch S.
        • Behrens M.
        • Foerch C.
        • Gehrig J.
        Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.
        Mult. Scler. Related Disord. 2019; 30: 33-37
        • Zachariou M.
        • Alexander S.P.
        • Coombes S.
        • Christodoulou C.A.
        biophysical model of endocannabinoid-mediated short term depression in hippocampal inhibition.
        PLoSOne. 2013; 8
        • Ziemann U.
        • Rothwell J.C.
        • Ridding M.C.
        Interaction between intracortical inhibition and facilitation in human motor cortex.
        J. Physiol. (Lond.). 1996; 496: 873-881
        • Ziemann U.
        • Reis J.
        • Schwenkreis P.
        • Rosanova M.
        • Strafella A.
        • Badawy R.
        • Müller-Dahlhaus F.
        TMS and drugs revisited.
        Clin Neurophysiol. 2014; 2015: 1847-1868